Загрузка...
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma
Ibrutinib has previously been shown to inhibit Bruton’s tyrosine kinase (BTK) and interleukin-2–inducible T-cell kinase (ITK), which mediate B-cell and T-cell receptor signaling, respectively. BTK inhibition with ibrutinib has demonstrated impressive clinical responses in a variety of B-cell maligna...
Сохранить в:
| Опубликовано в: : | Blood Adv |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Hematology
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5915998/ https://ncbi.nlm.nih.gov/pubmed/29669753 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017011916 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|